SANDBOX-&-CO
5.10.2022 14:01:50 CEST | Business Wire | Press release
Sandbox & Co, a London-based group operating a network of learning businesses, today announced that it has acquired award-winning UK-based children’s subscription service, toucanBox, which will sit within its newest division, Sandbox Experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005015/en/
Virginie Charles-Dear, Founder and CEO of toucanBox, UK-based children’s subscription service, that is now part of Sandbox & Co.’s rapidly expanding portfolio (Photo: Business Wire)
Inspired by Montessori learning and championing STEAM (science, technology, engineering, art, and maths), the newly acquired toucanBox provides fun educational opportunities for children aged 3 to 8 yrs. Through custom boxes posted through the letterbox, on a subscription or buy it now basis, it delivers craft materials and activities that help develop children’s key skills and support their cognitive and language development, fine motor skills and mental wellbeing.
‘We have been big fans of toucanBox and feel it is a perfect complement to our existing range of hands-on educational tools.’ said Bhav Singh, founder and CEO of Sandbox. ‘Creativity-filled fun learning is at the heart of what we do and I can’t wait to start working together on new experiences that will keep our users delighted and entertained.’
toucanBox will be joining the company’s new division, Sandbox Experiences, that currently includes Brazilian children’s book club, Leiturinha. Drawing on his expertise in growing Leiturinha into the largest kids book subscription service in Brazil, Sandbox Experiences’ lead, Guilherme Martins, will be focusing on rolling out new products across new markets, including in the USA and Europe.
‘Our goal is to deliver fun-filled learning opportunities for children aged 0-12 around the world’, said Guilherme Martins, president at Sandbox Experiences. ‘toucanBox is the perfect extension to our existing offering and I look forward to collaborating with the team on delivering even more engaging educational opportunities to help improve learning worldwide.’
‘toucanBox is all about learning through hands-on, fun activities and we are excited to join forces with Sandbox to accelerate our growth and pursue our mission to unleash children’s creativity’, said Virginie Charles-Dear, Founder and CEO of toucanBox. ‘We’re looking forward to expanding our product range further and reaching even more families in Europe and across the world.’
Sandbox has seen rapid growth over the last 5 years, and its current portfolio now consists of 18 brands with a peak monthly audience of 65M+ kids, families, and teachers. Its award-winning properties include Code Kingdoms, online coding courses for kids, Hopster, preschool learning platform, and Spanish companies Edujoy and Tellmewow. The company has been acquisitive and continues to focus on its buy and build strategy.
For logo and images click HERE
About Sandbox & Co – https://sandboxandco.com
Sandbox & Co is a London-based group operating a network of learning businesses providing an unparalleled ecosystem of edutainment products that reaches over 65 million children, their parents, and teachers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom